Respiratory motion-correction for CO2-stress PET imaging

Vascularix是Thornhill科学有限公司的全资子公司。它是多伦多大学健康网络的一个分支。我们正在商业化呼吸器系统，它控制肺部和血液中的气体浓度，作为一种非侵入性的，无药物的，用于心脏血流测试的应激剂。心脏压力测试是为了识别心脏病患者，并指导治疗。在超过500例的临床病例中，呼吸器系统被用作脑血管评估的科学工具，产生了40多篇基于脑血管反应性的同行评审出版物。Vascularix正在寻求将呼吸器首先用于心脏应激测试适应症的商业化，因为预期的采用和报销前景比迄今为止研究的大脑适应症更有利。

Vascularix is a wholly-owned subsidiary of Thornhill Scientific lnc., a spin-off of Toronto's University Health Network. We are commercializing the RespirAct system, which controls gas concentrations in the lungs and blood, as a non-invasive, drug-free, stress agent for use in cardiac blood flow testing. Cardiac stress testing is performed to identify patients with heart disease, and to guide treatment. The RespirAct system has been used as a scientific tool for brain vascular assessment in over 500 clinical cases resulting in over 40 peer-reviewed publications primarily based on brain vascular reactivity. Vascularix is pursuing the commercialization of RespirAct for the cardiac stress test indication first, as the expected adoption and reimbursement landscape is more favorable than for the brain indications studied to date.